CPRX · As filed with the SEC
Catalyst Pharmaceuticals income statement, by fiscal year
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenues: | ||||||||
| Total revenues | 588,989,000 | 491,734,000 | 398,204,000 | 214,203,000 | 140,833,000 | 118,740,617 | 102,306,337 | — |
| Product | — | — | — | — | — | — | 102,306,337 | — |
| Collaborative Arrangement Product Agreement | — | — | — | — | — | — | 0 | — |
| Revenues from collaborative arrangements | — | — | — | — | — | 332,186 | — | — |
| Total revenues | — | — | — | — | — | 119,072,803 | — | 500,000 |
| License and other revenue | 182,000 | 2,407,000 | 1,702,000 | 265,000 | 2,836,000 | — | — | — |
| Product revenue, net | 588,807,000 | 489,327,000 | 396,502,000 | 213,938,000 | 137,997,000 | — | — | — |
| Operating costs and expenses: | ||||||||
| Cost of sales | 87,253,000 | 68,845,000 | 51,967,000 | 34,393,000 | 21,884,000 | 17,039,157 | 14,759,139 | — |
| Research and development | 12,709,000 | 12,648,000 | 93,150,000 | 19,789,000 | 16,936,000 | 16,496,715 | 18,842,752 | 19,919,204 |
| General and administrative | — | — | — | — | — | — | — | 15,875,961 |
| Total operating costs and expenses | — | — | — | — | — | — | — | 35,795,165 |
| Selling, general and administrative | 193,751,000 | 177,740,000 | 133,710,000 | 58,183,000 | 49,628,000 | 44,233,754 | 36,881,187 | — |
| Total operating costs and expenses | — | — | — | — | 88,448,000 | 77,769,626 | 70,483,078 | — |
| Amortization of intangible assets | 37,498,000 | 37,377,000 | 32,565,000 | — | — | — | — | — |
| Total operating costs and expenses | 331,211,000 | 296,610,000 | 311,392,000 | 112,365,000 | — | — | — | — |
| Operating income | 257,778,000 | 195,124,000 | 86,812,000 | 101,838,000 | 52,385,000 | 41,303,177 | 31,823,259 | (35,295,165) |
| Other income, net | 25,737,000 | 21,139,000 | 7,699,000 | 2,881,000 | 282,000 | 586,897 | 1,585,774 | 1,291,651 |
| Net income before income taxes | 283,515,000 | 216,263,000 | 94,511,000 | 104,719,000 | 52,667,000 | 41,890,074 | 33,409,033 | (34,003,514) |
| Income tax provision | 69,189,000 | 52,374,000 | 23,101,000 | 21,640,000 | 13,185,000 | (33,092,926) | 1,533,696 | 0 |
| Net income | 214,326,000 | 163,889,000 | 71,410,000 | 83,079,000 | 39,482,000 | 74,983,000 | 31,875,337 | (34,003,514) |
| Net loss per share - basic and diluted | — | — | — | — | — | — | — | (0.33) |
| Weighted average shares outstanding - basic and diluted | — | — | — | — | — | — | — | 102,633,884 |
| Net income per share: | ||||||||
| Basic | 1.75 | 1.38 | 0.67 | 0.8 | 0.38 | 0.72 | 0.31 | — |
| Diluted | 1.68 | 1.31 | 0.63 | 0.75 | 0.37 | 0.71 | 0.3 | — |
| Weighted average shares outstanding: | ||||||||
| Basic | 122,290,866 | 118,457,673 | 106,279,736 | 103,374,606 | 103,379,349 | 103,512,913 | 102,944,316 | — |
| Diluted | 127,257,929 | 124,943,603 | 113,753,154 | 111,375,631 | 107,795,585 | 106,242,273 | 106,020,936 | — |
| Other comprehensive income (Note 4): | ||||||||
| Unrealized gain (loss) on available-for-sale securities, net of tax of $0, ($20) and $4, respectively | (64,000) | 50,000 | (10,000) | 172,000 | (179,000) | 21,827 | 29,753 | (20,248) |
| Comprehensive income | 214,262,000 | 163,939,000 | 71,400,000 | 83,251,000 | 39,303,000 | 75,004,827 | 31,905,090 | (34,023,762) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.